Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 1.89 percent increase over losses of $(0.53) per share from
Cogent Biosciences lost less money per share than experts predicted, which is good news for a company still in growth mode. When a company beats expectations—even on losses—it shows they're managing their spending better than people thought.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.